Skip to main content
Premium Trial:

Request an Annual Quote

NIAID to Fund Nonhuman Primate Genomics Lab for AIDS Studies

NEW YORK (GenomeWeb News) – The National Institute of Allergy and Infectious Diseases plans to fund one contractor to run a lab that will conduct genomics activities to support its Simian Vaccine Evaluation Unit, or SVEU, contract sites and research funded through its Division of Acquired Immune Deficiency Syndrome, or DAIDS.

The Nonhuman Primate Core Functional Genomics Laboratory for AIDS Vaccine Research and Development will use and improve assays to generate quantitative genomic expression profiles and network diagrams from RNA samples, NIAID said in a recent notice.

The contractor will be responsible for compiling and analyzing data from NHP research projects using bioinformatics and biocomputing tools.

NIAID expects to fund a contract for a one-year base period and four one-year options for a total of up to five years, beginning in the summer of 2013.

The functional genomics lab will join three existing NHP facilities, including the Cellular Immunology Core Lab, the Viral Ribonucleic Acid Core Lab, and the Humoral Immunology Core Lab, and it will be tasked with insuring standardization and comparability of functional genomics services and assays conducted for the SVEU and DAIDS-supported clinical studies.

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.